Three times as many patients hitting a durable hemoglobin target versus placebo is a clinically meaningful gap, but the number that carries more immediate weight is 1 g/dL: that is how much mean hemoglobin improved in the nipocalimab 30 mg/kg group by the end of Week 1, a speed that matters enormously in a condition where red blood cell destruction is ongoing and transfusions carry their own risks. Johnson & Johnson presented full results from the Phase 2/3 ENERGY trial at EHA 2026, and these data now anchor an sBLA that has already received FDA Priority Review for warm autoimmune hemolytic anemia (wAIHA).
The trial enrolled 115 adults, randomized roughly 1:1:1 across two nipocalimab dose schedules and placebo, in a multicenter, double-blind, placebo-controlled design. The primary endpoint was stringent: hemoglobin at or above 10 g/dL, an increase from baseline of at least 2 g/dL, sustained across three or more visits spanning at least 28 days beginning no earlier than Week 16, and achieved without rescue therapy. That design filters out transient responders. Nearly two-thirds of patients in the 30 mg/kg arm met both the hemoglobin concentration and the absolute increase targets by Week 24. Fatigue scores on the FACIT-Fatigue scale improved by a mean of 3.51 points over placebo, with signal appearing as early as Week 2. Corticosteroid dose reduction was also numerically higher in the nipocalimab arm, 15 percent versus 4 percent from baseline, a finding that matters given how heavily wAIHA management has historically leaned on corticosteroids and broad immunosuppressants in the absence of dedicated approved options.
The mechanistic argument here is worth taking seriously. Nipocalimab blocks the neonatal Fc receptor, reducing circulating IgG autoantibodies without broadly depleting B cells or impairing other immune pathways. That selectivity is not just a marketing distinction: patients with wAIHA often carry comorbid autoimmune conditions and infections risk is a real concern with aggressive immunosuppression. IMAAVY was approved for generalized myasthenia gravis in April 2025, and the safety profile observed in ENERGY, where the most common adverse events were peripheral edema, diarrhea, and fever, was consistent with that established record. No new signals emerged.
The FDA’s Priority Review designation accelerates the review clock, but it does not guarantee approval, and the agency will scrutinize the corticosteroid-reduction data closely because that endpoint did not clear the hierarchical multiplicity threshold as statistically significant. The single number to track now is the PDUFA date: whenever J&J discloses it, that deadline will determine whether nipocalimab becomes the first drug with a wAIHA-specific label and reshapes how hematologists sequence therapy from diagnosis onward.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
FDA Approves IMAAVY (Nipocalimab) for Warm Autoimmune Hemolytic Anemia
2 months ago[…] and broad immunosuppressants, neither of which targets the pathogenic IgG driving the destruction. IMAAVY is a selective FcRn blocker, designed to reduce circulating IgG autoantibodies while preserving […]
Comments are closed.